ID   T-47D Tam2
AC   CVCL_A4AP
DR   ATCC; CRL-3437
DR   cancercelllines; CVCL_A4AP
DR   Wikidata; Q105511143
RX   PubMed=27378269;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0553 ! T-47D
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=27378269; DOI=10.1186/s12885-016-2452-5;
RA   Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P.,
RA   Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.;
RT   "Systematic drug screening reveals specific vulnerabilities and
RT   co-resistance patterns in endocrine-resistant breast cancer.";
RL   BMC Cancer 16:378.1-378.17(2016).
//